Truist analyst Les Sulewski raised the firm’s price target on Collegium Pharmaceutical (COLL) to $58 from $55 and keeps a Buy rating on the shares. The firm is positive on the company’s Jornay momentum and pain portfolio durability, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COLL:
- Collegium Pharmaceutical management to meet with Truist
- Collegium price target lowered to $56 from $58 at Barclays
- Collegium Pharmaceutical price target raised to $60 from $46 at H.C. Wainwright
- Collegium Pharmaceutical: Strengthened 2026 Outlook, Balance Sheet Flexibility, and BD Upside Support Buy Rating and Higher Target
- Collegium Issues 2026 Guidance Emphasizing Jornay PM Growth